Evidence map›Paper›PMID 42756742›Full record

ArticleACS omega2026

Overcoming Docetaxel Resistance in Prostate Cancer by Targeting Cell Cycle Progression with Narciclasine-Based Compounds.

Ranyelison Silva Machado, Kaio S Gomes, Augusto B Farias, Natália Meneses Araújo, Giovanna Barbosa Chanes, Laura Maria Pinto Dias, Bianca Zaia Franco Ferreira, Carla Cristina Lopes, Ileana G S Rubio, Fernando Moreira Simabuco and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ranyelison Silva MachadoCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Kaio S GomesCenter for Natural and Human Sciences, Federal University of ABC, Santo Andre São Paulo 09210-180, Brazil.
Augusto B FariasCenter for Natural and Human Sciences, Federal University of ABC, Santo Andre São Paulo 09210-180, Brazil.
Natália Meneses AraújoCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Giovanna Barbosa ChanesCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Laura Maria Pinto DiasCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Bianca Zaia Franco FerreiraDepartment of Biochemistry, Federal University of São Paulo, São Paulo, São Paulo 04044-020, Brazil.
Carla Cristina LopesDepartment of Biochemistry, Federal University of São Paulo, São Paulo, São Paulo 04044-020, Brazil.
Ileana G S RubioCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Fernando Moreira SimabucoDepartment of Biochemistry, Federal University of São Paulo, São Paulo, São Paulo 04044-020, Brazil.
Daniela G G RandoPosgraduate Program of Chemical Biology, Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo, Diadema São Paulo 09972-270, Brazil.ORCID https://orcid.org/0000-0002-6586-5107
Hugo Pequeno MonteiroDepartment of Biochemistry, Center for Cellular and Molecular Therapy - CTCMol, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.
Adolfo Garcia ErustesPharmacology Department, Federal University of São Paulo, São Paulo, São Paulo 04044-020, Brazil.
Soraya Soubhi SmailiPharmacology Department, Federal University of São Paulo, São Paulo, São Paulo 04044-020, Brazil.
David RyffelDepartment of Chemistry, Wiess School of Natural Sciences, Rice University, Houston, Texas 770055, United States.ORCID https://orcid.org/0000-0001-7094-9826
David SarlahDepartment of Chemistry, Wiess School of Natural Sciences, Rice University, Houston, Texas 770055, United States.ORCID https://orcid.org/0000-0002-8736-8953
Giselle CerchiaroCenter for Natural and Human Sciences, Federal University of ABC, Santo Andre São Paulo 09210-180, Brazil.ORCID https://orcid.org/0000-0001-8606-5400
João Henrique G LagoCenter for Natural and Human Sciences, Federal University of ABC, Santo Andre São Paulo 09210-180, Brazil.ORCID https://orcid.org/0000-0002-1193-8374
Rodrigo Esaki TamuraCancer Molecular Biology Laboratory, Federal University of São Paulo, São Paulo, São Paulo 04039-032, Brazil.ORCID https://orcid.org/0000-0001-7767-0887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of resistance to taxane-based chemotherapy, specifically docetaxel (DTX), in advanced prostate cancer is frequent. Natural compounds, such as narciclasine, an alkaloid derived from plants, offer a potentially advantageous approach. Docetaxel-resistant prostate cancer cell lines (DU145RST and PC3RST) were established and treated with narciclasine (

Identifiers

PMID42756742
PMCPMC13584155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.